This page contains exclusive content for the member of the following sections: TTS, ITA. Log in to view.

Disease-modifying therapy in short bowel syndrome

142.1 - Disease-modifying therapy in short bowel syndrome

Presenter: Palle Bekker Jeppesen, Francisca Joly , ,
Authors: Palle Bekker Jeppesen, Francisca Joly, Tim Vanuytsel

IRTA Webinar - October 19, 2021

Disease-modifying therapy in short bowel syndrome

Tuesday, October 19, 2021, 2:00 PM


Short-bowel syndrome is the most common cause of intestinal failure. Until recently, management options were limited to dietary support, anti-secretory drugs and anti-motility agents. The introduction of GLP-2 analogues have drastically changed the field, offering disease-modifying therapy which can lead to reduction of parenteral support. However, several questions remain: which is the ideal target population? When should treatment be started? Can the treatment frequency be reduced after full weaning? And how should the care for a patient treated with GLP-2 analogues be embedded in a multidisciplinary approach?

Learning Objectives

  1. To understand the mechanism of action of GLP-2 analogues in short-bowel syndrome.
  2. To know the expected clinical effects and adverse events during treatment with GLP-2 analogues.
  3. To know the predictors of response to GLP-2 analogues.
  4. To understand the multidisciplinary management of a patient treated with GLP-2 analogues.
Tim Vanuytsel
Leuven University Hospital
Palle Bekker Jeppesen
Department of Intestinal Failure and Liver Diseases, Rigshospitalet
Francisca Joly 
Beaujon Hospital – University of Paris

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.



Staff Directory


The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6